Corona crisis has limited impact on infant participation in National Immunisation Programme Nearly all infants in the Netherlands are still participating in the National Immunisation Programme.
Initial results on how COVID-19 spreads within Dutch families The novel coronavirus is primarily spread amongst adults who are about the same age. Within families, the virus is mainly transmitted from adults to children.
Tuberculosis control in the Netherlands: current situation and five-year plan Every year on 24 March, the world marks ‘World TB Day’ to raise awareness for the global fight against tuberculosis (TB)– one of the world’s top infectious killers.
New possibilities for the responsible recycling of plastics RIVM proposes the consideration of a broader environmental perspective in the trade-off between incineration and recycling of plastics.
More tobacco products, number of additives stable In 2014, the number of tobacco products on the Dutch market increased to 4212. This is a 5 percent increase compared to 2013.
Discussions on internet forums as a valuable source to understand patients’ perspectives Patients' perspectives do not always correspond to those of healthcare professionals and policy-makers.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
INHERIT research project kicks off Maximising health equity and environmental sustainability: the INter-sectoral Health and Environment Research for InnovaTions (INHERIT) project has kicked off. RIVM experts joined 17
Risk of degradation of European ecosystems by air pollution is decreasing The number of natural areas in Europe that are threatened by air pollution will decrease between 2005 and 2020.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.